Therapeutic area

Skin and subcutaneous tissue disorders – page 39

849 clinical trials
267 recruiting
359 conditions
25 countries

Clinical trials in Skin and subcutaneous tissue disorders

849 trials across Europe, recruiting first

Click a country to filter the trials

Quick filters

849 clinical trials

Dermatitis atopic

Not recruiting

Study on Long-Term Safety and Efficacy of Amlitelimab for Patients with Moderate to Severe Atopic Dermatitis from Previous Trials

Registered drugNo placebo

Study on Long-Term Safety and Efficacy of Amlitelimab for Patients with Moderate to Severe Atopic Dermatitis from Previous Trials

Registered drugNo placebo

Bulgaria

Participants:0–17 years · 18–64 years · 65+ years
Substances:Amlitelimab
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Psoriatic arthropathy

Not recruiting

Study on Deucravacitinib for Patients with Active Psoriatic Arthritis New to Biologic Treatments

Investigational

Study on Deucravacitinib for Patients with Active Psoriatic Arthritis New to Biologic Treatments

Investigational

Bulgaria

Participants:18–64 years · 65+ years
Substances:Deucravacitinib
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Neurodermatitis

Not recruiting

Study on the Effectiveness and Safety of Ruxolitinib Cream for Patients with Prurigo Nodularis

Investigational

Study on the Effectiveness and Safety of Ruxolitinib Cream for Patients with Prurigo Nodularis

Investigational

Austria

Participants:18–64 years · 65+ years
Substances:Ruxolitinib
Sponsor:Incyte Corp.

Contact Research Centre

Systemic scleroderma

Not recruiting

Study on BI 685509 for Adults with Systemic Sclerosis to Assess Effects on Lung Function and Symptoms

Investigational

Study on BI 685509 for Adults with Systemic Sclerosis to Assess Effects on Lung Function and Symptoms

Investigational

Austria

Participants:18–64 years
Substances:BI 685509
Sponsor:Boehringer Ingelheim Espana S.A.

Contact Research Centre

Psoriatic arthropathy

Not recruiting

Study on Long-Term Safety and Efficacy of Tildrakizumab for Adults with Psoriatic Arthritis

Registered drugNo placebo

Study on Long-Term Safety and Efficacy of Tildrakizumab for Adults with Psoriatic Arthritis

Registered drugNo placebo

Czechia

Participants:18–64 years · 65+ years
Substances:Tildrakizumab
Sponsor:Sun Pharmaceutical Industries Limited

Contact Research Centre

Psoriatic arthropathy

Not recruiting

Study on Izokibep for Improving Symptoms in Patients with Active Psoriatic Arthritis

Investigational

Study on Izokibep for Improving Symptoms in Patients with Active Psoriatic Arthritis

Investigational

Bulgaria

Participants:18–64 years · 65+ years
Substances:Izokibep
Sponsor:Acelyrin Inc.

Contact Research Centre

Systemic lupus erythematosus

Not recruiting

Study on the Effectiveness and Safety of Deucravacitinib for Patients with Active Systemic Lupus Erythematosus (SLE)

Investigational

Study on the Effectiveness and Safety of Deucravacitinib for Patients with Active Systemic Lupus Erythematosus (SLE)

Investigational

Bulgaria

Participants:18–64 years · 65+ years
Substances:Deucravacitinib
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Systemic lupus erythematosus

Not recruiting

Study on the Effectiveness and Safety of Deucravacitinib for Patients with Active Systemic Lupus Erythematosus (SLE)

Investigational

Study on the Effectiveness and Safety of Deucravacitinib for Patients with Active Systemic Lupus Erythematosus (SLE)

Investigational

Bulgaria

Participants:18–64 years · 65+ years
Substances:Deucravacitinib
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Dermatitis atopic

Not recruiting

Study on the Long-term Safety and Effectiveness of Lebrikizumab for Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis

InvestigationalNo placebo

Study on the Long-term Safety and Effectiveness of Lebrikizumab for Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis

InvestigationalNo placebo

Germany

Participants:0–17 years · 18–64 years · 65+ years
Substances:Lebrikizumab
Sponsor:Almirall S.A.

Contact Research Centre

Dermatitis atopic+1

Not recruiting

Study of Lebrikizumab and Topical Corticosteroids for Children and Teens with Moderate-to-Severe Atopic Dermatitis

Registered drug

Study of Lebrikizumab and Topical Corticosteroids for Children and Teens with Moderate-to-Severe Atopic Dermatitis

Registered drug

Czechia

Participants:0–17 years
Substances:Glucocorticoids
Sponsor:Eli Lilly & Co.

Contact Research Centre

Psoriasis

Not recruiting

Study on the Effectiveness and Safety of DC-806 for Adults with Moderate to Severe Plaque Psoriasis

Investigational

Study on the Effectiveness and Safety of DC-806 for Adults with Moderate to Severe Plaque Psoriasis

Investigational

Czechia

Participants:18–64 years · 65+ years
Substances:DC-806
Sponsor:DICE Therapeutics Inc.

Contact Research Centre

Systemic lupus erythematosus

Not recruiting

Study on the Safety and Effectiveness of ESK-001 for Adults with Systemic Lupus Erythematosus

Investigational

Study on the Safety and Effectiveness of ESK-001 for Adults with Systemic Lupus Erythematosus

Investigational

Bulgaria

Participants:18–64 years · 65+ years
Substances:ESK-001
Sponsor:Alumis Inc.

Contact Research Centre

Substances studied in this area

The therapies tested most often in Skin and subcutaneous tissue disorders trials.

Pembrolizumab57 clinical trials Nivolumab33 clinical trials Sodium Chloride22 clinical trials Deucravacitinib19 clinical trials Cemiplimab18 clinical trials Upadacitinib17 clinical trials Ipilimumab15 clinical trials Rituximab13 clinical trials Cyclophosphamide12 clinical trials

Skin and subcutaneous tissue disorders – page 39

Conditions in this area

Clinical trials in Skin and subcutaneous tissue disorders

849 clinical trials

Dermatitis atopic

Study on Long-Term Safety and Efficacy of Amlitelimab for Patients with Moderate to Severe Atopic Dermatitis from Previous Trials

Psoriatic arthropathy

Study on Deucravacitinib for Patients with Active Psoriatic Arthritis New to Biologic Treatments

Neurodermatitis

Study on the Effectiveness and Safety of Ruxolitinib Cream for Patients with Prurigo Nodularis

Systemic scleroderma

Study on BI 685509 for Adults with Systemic Sclerosis to Assess Effects on Lung Function and Symptoms

Psoriatic arthropathy

Study on Long-Term Safety and Efficacy of Tildrakizumab for Adults with Psoriatic Arthritis

Psoriatic arthropathy

Study on Izokibep for Improving Symptoms in Patients with Active Psoriatic Arthritis

Systemic lupus erythematosus

Study on the Effectiveness and Safety of Deucravacitinib for Patients with Active Systemic Lupus Erythematosus (SLE)

Systemic lupus erythematosus

Study on the Effectiveness and Safety of Deucravacitinib for Patients with Active Systemic Lupus Erythematosus (SLE)

Dermatitis atopic

Study on the Long-term Safety and Effectiveness of Lebrikizumab for Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis

Dermatitis atopic+1

Study of Lebrikizumab and Topical Corticosteroids for Children and Teens with Moderate-to-Severe Atopic Dermatitis

Psoriasis

Study on the Effectiveness and Safety of DC-806 for Adults with Moderate to Severe Plaque Psoriasis

Systemic lupus erythematosus

Study on the Safety and Effectiveness of ESK-001 for Adults with Systemic Lupus Erythematosus

Filter the trials

Substances studied in this area

Prefer not to search? Our Concierge searches the trials for you.